Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German biotech Rigontec closes second series A financing

This article was originally published in Scrip

Executive Summary

The private German company Rigontec has raised €4.8m in a second closing of its series A financing financing round, bringing the total to €14.25m, which it will use to move its lead drug candidate into clinical proof-of-concept studies, and to expand its pipeline based on its proprietary RNA-sensing technology. Rigontec is developing RNA-based immunotherapeutics for cancer and viral diseases by developing synthetic ligands of a novel receptor of the innate immune system, retinoic acid inducible gene I (RIG-I), which recognizes viral RNA. RNA motifs that activate RIG-I promote the destruction of diseased cells and the induction of a lasting immune memory to treat as well as preventing recurrence of disease. The latest financing was from the Dutch VC Forbion Capital Partners, and Copenhagen-based Sunstone Capital, adding to original investors Wellington Partners, Boehringer Ingelheim Venture Fund, NRW.BANK and High-Tech Gründerfonds (HTGF). Rigontec was spun out in January 2014 from the Institute for Clinical Chemistry and Clinical Pharmacology at the University Hospital of the University of Bonn, Germany.

You may also be interested in...

Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole

Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.

mRNA Vaccines – Trials Line Up Against Coronavirus

The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.

Novartis Close To EU Approval For Zolgensma At Last

Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts